
## Howard J Lim

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5178970/publications.pdf Version: 2024-02-01



HOWARD LLIM

#	Article	IF	CITATIONS
1	Viral Disease Goes Viral: Characterizing How Cancer Patients Use Internet Resources for COVID-19 Information. Journal of Cancer Education, 2023, 38, 431-439.	1.3	1
2	Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care. Journal of Community Genetics, 2022, 13, 523-538.	1.2	4
3	FDA Accelerated Approval for Malignant Hematology and Oncology Indications in the Canadian Environment. Current Oncology, 2022, 29, 402-410.	2.2	1
4	Defining a Core Data Set for the Economic Evaluation of Precision Oncology. Value in Health, 2022, 25, 1371-1380.	0.3	6
5	Uncovering Clinically Relevant Gene Fusions with Integrated Genomic and Transcriptomic Profiling of Metastatic Cancers. Clinical Cancer Research, 2021, 27, 522-531.	7.0	14
6	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 202-212.	7.0	50
7	Matching methods in precision oncology: An introduction and illustrative example. Molecular Genetics & Genomic Medicine, 2021, 9, e1554.	1.2	13
8	Readiness of Healthcare Systems to Generate Real-World Evidence: Reliability of CT Radiographic End Points for Evaluation of First-Line Systemic Treatment. JCO Oncology Practice, 2021, 17, OP.20.00810.	2.9	0
9	Modelling hereditary diffuse gastric cancer initiation using transgenic mouseâ€derived gastric organoids and singleâ€cell sequencing. Journal of Pathology, 2021, 254, 254-264.	4.5	11
10	lgG4-Related Disease as Mimicker of Malignancy. SN Comprehensive Clinical Medicine, 2021, 3, 1904-1913.	0.6	7
11	Clinical and cost outcomes following genomicsâ€informed treatment for advanced cancers. Cancer Medicine, 2021, 10, 5131-5140.	2.8	8
12	Canadian Regulatory and Health Technology Assessment for Malignant Hematology and Oncology Indications Compared With the US Food and Drug Administration Accelerated Approval Program. JAMA Network Open, 2021, 4, e2120301.	5.9	0
13	A Hypothesis-Generating Study Using Electrophysiology to Examine Cognitive Function in Colon Cancer Patients. Archives of Clinical Neuropsychology, 2020, 35, 226-232.	0.5	2
14	Establishing a Framework for the Clinical Translation of Germline Findings in Precision Oncology. JNCI Cancer Spectrum, 2020, 4, pkaa045.	2.9	6
15	Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system. Cancer Medicine, 2020, 9, 6507-6514.	2.8	5
16	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-5.	1.9	6
17	Improved structural variant interpretation for hereditary cancer susceptibility using long-read sequencing. Genetics in Medicine, 2020, 22, 1892-1897.	2.4	42
18	Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. Journal of Physical Education and Sports Management, 2020, 6, a004713.	1.2	5

HOWARD J LIM

#	Article	IF	CITATIONS
19	Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer, 2020, 1, 452-468.	13.2	103
20	Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1110-1117.	1.5	7
21	Application of a Neural Network Whole Transcriptome–Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers. JAMA Network Open, 2019, 2, e192597.	5.9	67
22	Base excision repair deficiency signatures implicate germline and somatic <i>MUTYH</i> aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Journal of Physical Education and Sports Management, 2019, 5, a003681.	1.2	33
23	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 196-201.	1.3	12
24	Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. Journal of Physical Education and Sports Management, 2019, 5, a002659.	1.2	3
25	Molecular characterization of <i>ERBB2</i> -amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Journal of Physical Education and Sports Management, 2018, 4, a002535.	1.2	16
26	Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision-making. Journal of Physical Education and Sports Management, 2018, 4, a002626.	1.2	18
27	Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. Npj Precision Oncology, 2018, 2, 8.	5.4	15
28	Primary Care Versus Oncology-Based Surveillance Following Adjuvant Chemotherapy in Resected Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2018, 49, 429-436.	1.3	4
29	Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing. Journal of Physical Education and Sports Management, 2018, 4, a002329.	1.2	30
30	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 552-554.	1.3	19
31	Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer. Clinical Cancer Research, 2017, 23, 7521-7530.	7.0	144
32	Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2016, 15, 179-185.	2.3	38
33	Effect of Adjuvant Chemotherapy on Stage II Rectal Cancer Outcomes After Preoperative Short-Course Radiotherapy. Clinical Colorectal Cancer, 2016, 15, 352-359.e1.	2.3	12
34	Image-Guided Biopsy in the Era of Personalized Cancer Care: Proceedings from the Society of Interventional Radiology Research Consensus Panel. Journal of Vascular and Interventional Radiology, 2016, 27, 8-19.	0.5	87
35	Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes. Clinical Colorectal Cancer, 2016, 15, 16-23.	2.3	20
36	Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Journal of Physical Education and Sports Management, 2015, 1, a000570.	1.2	92

Howard J Lim

#	Article	IF	CITATIONS
37	Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2015, 14, 262-268.e1.	2.3	17
38	Comparison of Toxicity Experienced by Older Versus Younger Patients Enrolled in Breast Cancer Clinical Trials. Clinical Breast Cancer, 2015, 15, 73-79.	2.4	13
39	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. Clinical Colorectal Cancer, 2015, 14, 25-30.	2.3	14
40	Colonoscopy after CT-diagnosed acute diverticulitis: Is it really necessary?. Canadian Journal of Surgery, 2015, 58, 226-231.	1.2	24
41	Surveillance for asymptomatic recurrence in resected stage III colon cancer: does it result in a more favorable outcome?. Journal of Gastrointestinal Oncology, 2015, 6, 268-73.	1.4	3
42	ARID1A/BAF250a as a prognostic marker for gastric carcinoma: a study of 2 cohorts. Human Pathology, 2014, 45, 1258-1268.	2.0	34
43	Outcomes of patients treated with capecitabine and temozolamide for advanced pancreatic neuroendocrine tumors (PNETs) and non-PNETs. Journal of Gastrointestinal Oncology, 2014, 5, 247-52.	1.4	42
44	Acute gout episodes during treatment with capecitabine: a case report. Gastrointestinal Cancer Research: GCR, 2014, 7, 59-60.	0.7	2
45	Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study. Journal of Oncology Practice, 2009, 5, 153-158.	2.5	13
46	Controlling the Drug Delivery Attributes of Lipid-Based Drug Formulations. Journal of Liposome Research, 1998, 8, 299-335.	3.3	34